PurposeTo identify triple-negative (TN) breast cancer imaging biomarkers in comparison to other molecular subtypes using multiparametric MR imaging maps and whole-tumor histogram analysis.Materials and methodsThis retrospective study included 134 patients with invasive ductal carcinoma. Whole-tumor histogram-based texture features were extracted from a quantitative ADC map and DCE semi-quantitative maps (washin and washout). Univariate analysis using the Student's t test or Mann-Whitney U test was performed to identify significant variables for differentiating TN cancer from other subtypes. The ROC curves were generated based on the significant variables identified from the univariate analysis. The AUC, sensitivity, and specificity for subtype differentiation were reported.ResultsThe significant parameters on the univariate analysis achieved an AUC of 0.710 (95% confidence interval [CI] 0.562, 0.858) with a sensitivity of 63.6% and a specificity of 73.1% at the best cutoff point for differentiating TN cancers from Luminal A cancers. An AUC of 0.763 (95% CI 0.608, 0.917) with a sensitivity of 86.4% and a specificity of 72.2% was achieved for differentiating TN cancers from human epidermal growth factor receptor 2 (HER2) positive cancers. Also, an AUC of 0.683 (95% CI 0.556, 0.809) with a sensitivity of 54.5% and a specificity of 83.9% was achieved for differentiating TN cancers from non-TN cancers. There was no significant feature on the univariate analysis for TN cancers versus Luminal B cancers.ConclusionsWhole-tumor histogram-based imaging features derived from ADC, along with washin and washout maps, provide a non-invasive analytical approach for discriminating TN cancers from other subtypes.Key Points center dot Whole-tumor histogram-based features on MR multiparametric maps can help to assess biological characterization of breast cancer.center dot Histogram-based texture analysis may predict the molecular subtypes of breast cancer.center dot Combined DWI and DCE evaluation helps to identify triple-negative breast cancer.
[1]Fudan Univ, Shanghai Canc Ctr, Dept Radiol, 270 Dongan Rd, Shanghai 200032, Peoples R China.
[2]Shanghai Univ Tradit Chinese Med, Longhua Hosp, Dept Radiol, Shanghai, Peoples R China.
[3]Siemens Shenzhen Magnet Resonance Ltd, MR Applicat Dev, Shenzhen, Peoples R China.
[4]Fudan Univ, Dept Pathol, Shanghai Canc Ctr, Shanghai, Peoples R China.
[5]Hangzhou Dianzi Univ, Inst Biomed Engn & Instrumentat, Hangzhou, Zhejiang, Peoples R China.
[6]Siemens Healthineers, MR Applicat Predev, Erlangen, Germany.
(8.0+极速模式)